🇨ðŸ‡Â·3h agoIndustry
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
Publisher
R
Roche Newsroom
Switzerland
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Roche Newsroom
- Region
- Switzerland
- Scope
- Industry
- Published
- September 18, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News/3h ago
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Merck & Co. (MSD) News/3h ago
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck & Co. (MSD) News/3h ago
Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
Aspen Pharmacare/7h ago